Letter to our stakeholders Financial highlights Diabetes care Haemostasis management Growth hormone therapy Hormone replacement therapy R&D Pipeline Legal notice

	Leadership in insulin delivery devices Raising diabetes awareness in India Internet services for people with diabetes Internet services for healthcare professionals Innovative insulin delivery Effective control of diabetes Community for growth hormone deficiency

	Is NovoSeven® a miracle drug? The DAWN of better understanding Overcoming the insulin barrier Fun and learning at diabetes summer camps Lower doses in hormone replacement therapy Growth hormone effective in SGA

	Improving access to health Novo Nordisk sponsors grants for diabetes Expanding diabetes care facilities in Latin America Linking treatment with teaching

	The promise of insulin analogues Research into possibility of an artificial pancreas Insulin saves lives of intensive care patients Lowering glucose and controlling bodyweight Controlling blood fat levels to save lives

	Focus on shareholder value Financial discussion Business with conscience Reporting on the Triple Bottom Line Questions from Investors Financial calendar for 2002 Board of Directors Corporate Management Financial definitions Medical glossary